Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J BUON ; 23(5): 1407-1412, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30570866

RESUMO

PURPOSE: Non-small lung cancer (NSLC) is one of the leading causes of cancer-related deaths world over. Excempting operable cases the treatments for NSCLC mainly include chemotherapy and radiotherapy. However, the survival rate for NSCLC is still far from satsifactory. Moreover, chemotherapy has lot of associated side effects. Therefore, there is an urgent need to look for novel and more viable treatment options. Against this background, the present study was designed to evaluate the anticancer activity of α-Bisabolol against NSCLC. METHODS: Cell viability was assessed by MTT assay. Apoptosis was determined by DAPI and annexin V/propidium iodide (PI) staining. Mitochondrial membrane potential (MMP) and cell cycle analysis were determined by flow cytometry. Cell migration was investigated by wound healing assay and protein expression was evaluated by western blotting. RESULTS: α-Bisabolol exerted significant anticancer activity on A549 NSCLC cells with IC50 of 15 µM. The anticancer effects of α-Bisabolol were found to be due to G2/M cell cycle arrest and mitochondrial apoptosis. α-Bisabolol also inhibited cell migration of A549 cells dose-dependently. Moreover, the results showed that α-Bisabolol could inhibit the PI3K/AKT signalling pathway in a dose-dependent manner. The results of the present study indicate that α-Bisabolol exerted selective anticancer effects on A549 cells via induction of cell cycle arrest, mitochondrial apoptosis and inhibition of PI3K/Akt signalling pathways. CONCLUSIONS: This molecule showed promising anticancer features and could be developed as a potent lead candidate for the management and treatment of NSCLC.


Assuntos
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Fosfatidilinositol 3-Quinases/metabolismo , Proteínas Proto-Oncogênicas c-akt/metabolismo , Sesquiterpenos/farmacologia , Células A549 , Apoptose/efeitos dos fármacos , Carcinoma Pulmonar de Células não Pequenas/metabolismo , Carcinoma Pulmonar de Células não Pequenas/patologia , Pontos de Checagem do Ciclo Celular/efeitos dos fármacos , Movimento Celular/efeitos dos fármacos , Separação Celular , Humanos , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/patologia , Sesquiterpenos Monocíclicos , Inibidores de Fosfoinositídeo-3 Quinase , Proteínas Proto-Oncogênicas c-akt/antagonistas & inibidores , Transdução de Sinais/efeitos dos fármacos , Regulação para Cima/efeitos dos fármacos
2.
Artigo em Zh | WPRIM | ID: wpr-668699

RESUMO

Laboratory animals are commonly used as experimental objects in medical research, and laboratory animal welfare is closely related with good scientific outcomes. It is important for researchers in hospitals to establish a concept of protecting the welfare of laboratory animals. In this paper, combined with our experience concerning with the ethics and animal welfare in recent years in Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School,we try to discuss the importance of animal experiments in the hospital,the significance of maintenance of laboratory animal welfare and the ethical review of the welfare of laboratory animals,etc.,in order to provide a reference to the protection of laboratory animal welfare for researchers in hospitals.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA